By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

A resurgence of interest One reason that ADCs struggled to gain traction is due to their potential for toxicity. Mylotarg (gemtuzumab ozogamicin) is an ADC created by Pfizer and approved in 2000 ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

"P-Sam is an exciting new ADC targeting B7-H4 ... unacceptable drug-related toxicity, or withdrawal of consent. Almost all patients in the study (94%) had received prior platinum chemotherapy ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in insightful discussions and building meaningful connections with industry ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

These assets are engineered to produce minimal off-target toxicity, with a higher therapeutic ... to swiftly advance our portfolio of promising ADC assets," said David Lennon, President and ...